PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease

The aim of the study was to apply Physiologically-Based Pharmacokinetic (PBPK) modelling to predict the effect of liver disease (LD) on the pharmacokinetics (PK) of dexamethasone (DEX) in the treatment of COVID-19. A whole-body PBPK model was created to simulate 100 adult individuals aged 18–60 year...

Descripción completa

Detalles Bibliográficos
Autores principales: Montanha, Maiara Camotti, Cottura, Nicolas, Booth, Michael, Hodge, Daryl, Bunglawala, Fazila, Kinvig, Hannah, Grañana-Castillo, Sandra, Lloyd, Andrew, Khoo, Saye, Siccardi, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832977/
https://www.ncbi.nlm.nih.gov/pubmed/35153785
http://dx.doi.org/10.3389/fphar.2022.814134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8832977/
https://www.ncbi.nlm.nih.gov/pubmed/35153785
http://dx.doi.org/10.3389/fphar.2022.814134

Ejemplares similares